General Info
4BIO Capital is a specialist fund focused on investing in and building early stage advanced therapy companies
Location: 78 Pall Mall, London, England, United Kingdom, SW1Y 5ES
Country: United Kingdom of Great Britain and Northern Ireland
Industries: BioTech,Healthcare,Life Science,Medical Device
Investment Regions: EU
Investment Stages: seed, series-a
Website: http://www.4biocapital.com
vc
EU
Want to start building warm intros with this investor?
🤖 AI Activity Report
Status: very-active
AI Reasoning: 4BIO Capital co-led a $75.5M Series A in Actithera with press release dated 9 July 2025 (invested in Actithera). From that date to Nov 1, 2025 is less than 4 months, which is within the <3 months? Wait calculate: July 9 to Nov 1 is 115 days ~3.8 months. Also 4BIO had a Oct 6, 2025 press release about Trogenix (dated Oct 6, 2025) – investment in Trogenix. That is within <3 months (Oct 6 to Nov 1 is 26 days). Therefore last known investment Oct 6, 2025 in Trogenix – less than 3 months. Tag accordingly.[/evc_normalize]
Here are the thresholds established for the different statuses:
Not Active – No known investments in the last 12 months.
Low Activity – Only known investments between the last 12 and 6 months.
Active – Known investments between the last 6 and 3 months.
Very Active – Known investments in the last 3 months.
Investor Contact
Team Members
Name
Role
Email
LinkedIn
Kieran …
Partner, General Counsel
…
…
…
…
Warm Intros from Portfolio Companies
Investment Regions Map
loading map…
Similar Investors
Other similar investors:
Latest on X (Twitter)
Access all contact details of 4BIO Capital
Gain instant access to partner names, verified emails, LinkedIn profiles, and more—all in one place. Dive into their portfolio founders and their LinkedIn information, so you can quickly start your outreach and look for warm intros.
Add custom tags to your investor cards. Label them by investment stage, industry focus, interest level, or any other criteria you want to stay organized.
Trusted by Founders like You
Find your matching investors using AI